SWX:SDZPharmaceuticals
Assessing Sandoz Group (SWX:SDZ) Valuation After Guidance, Dividend Increase And Ranluspec Approval
Sandoz Group (SWX:SDZ) just packed several developments into one week, combining full year 2025 results, fresh 2026 net sales guidance, a higher annual dividend, and new EU marketing authorization for its eye drug Ranluspec.
See our latest analysis for Sandoz Group.
The recent mix of higher 2025 sales and net income, fresh 2026 net sales guidance, a larger dividend and Ranluspec approval comes after a 1-day share price return of a 1.82% decline and a 7-day share price return of a 6.67%...